

21 Feb 2019 | News

QUOTED. Feb. 21, 2019. Damien McDonald.

by

Device-maker LivaNova will put its vagus nerve stimulation system to another sham-controlled test in patients with treatment-resistant depression by leveraging a newly finalized Medicare national coverage determination, which covers patients with bipolar disease. See what LivaNova CEO Damien McDonald said about it here.

"This decision will help the large number of people who suffer from TRD [treatment-resistant depression] receive access to an affordable, potentially life-altering treatment option." –Damien McDonald, CEO, LivaNova

- Find out more: [Vagus Nerve Stim Gets New Chance To Prove Its Worth For Depression](#)

[Click here](#) for a free trial of *Medtech Insight*